Affiliation:
1. Roche Molecular Systems, Inc., Branchburg, New Jersey 08876,1 and
2. New England Research Institutes, Watertown, Massachusetts 021722
Abstract
ABSTRACT
With the recent introduction of combination therapy, human immunodeficiency virus type 1 (HIV-1) RNA levels in plasma have been dramatically reduced, frequently to below the limit of quantitation (400 copies/ml of plasma) of the AMPLICOR HIV-1 MONITOR Test (Roche Diagnostic Systems). To achieve enhanced sensitivity of the AMPLICOR HIV-1 MONITOR Test, a modified specimen preparation procedure that allows input of RNA from 10-fold more plasma per amplification reaction was developed. This “ultrasensitive” method allows the accurate quantitation of plasma HIV-1 RNA levels as low as 50 copies/ml. A precision study yielded average within-run and between-run coefficients of variation (CV) of 24.8 and 9.6%, respectively. A multicenter reproducibility study demonstrated that the laboratory-to-laboratory reproducibility of this assay is good, with an average CV of 32%. The linear range of this test is between 50 and 50,000 copies/ml of plasma. RNA concentrations measured by the ultrasensitive and standard HIV-1 MONITOR tests exhibited good agreement within the shared linear range of the two methods. The two measurements were within a factor of 2 for 91% of the specimens tested, with the concentration measured by the ultrasensitive method being only slightly lower (median, 22% lower). Preliminary studies suggest that this assay will prove to be useful for predicting the stability of viral suppression in patients whose RNA levels drop below 400 copies/ml in response to highly active antiretroviral therapy.
Publisher
American Society for Microbiology
Reference30 articles.
1. British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals;BHIVA Guidelines Co-ordinating Committee;Lancet,1997
2. Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel;Carpenter C. C.;JAMA,1996
3. Public Health Service task force recommendations for the use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States;Centers for Disease Control and Prevention;Morbid. Mortal. Weekly Rep.,1998
4. Guidelines for the use of antiretroviral agents in pediatric HIV infection;Centers for Disease Control and Prevention;Morbid. Mortal. Weekly Rep.,1998
5. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter;Eron J. J.;N. Engl. J. Med.,1995
Cited by
116 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献